Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > REGULATORY
REGULATORY
- MOF Panel’s Proposal Urges More Stringent Drug Cost Control, Revisiting of Semi-Automatic Listing
May 24, 2021
- Biz Improvement Order Issued to 3 Codevelopers over Kobayashi Kako’s Fudged Data
May 24, 2021
- LDP Project Team Submits Proposal to Boost Drug Discovery Capabilities
May 24, 2021
- PMDA Review Report: Flexible Discussions Needed for Eligibility of AstraZeneca Vaccine
May 24, 2021
- PMDA Reviewing New Safety Risk for Keytruda
May 24, 2021
- Japan Approves Moderna and AstraZeneca COVID-19 Vaccines
May 21, 2021
- AstraZeneca, Moderna COVID-19 Vaccines in Line for Japan Approval on May 21
May 21, 2021
- Give AstraZeneca Shots to People Who Want, Regardless of Priority Order: Lawmakers
May 21, 2021
- Japan Govt Eyes Expedited Approval Process to Push Homegrown Vaccines
May 20, 2021
- LDP Panels Submit Proposal to PM for Commercialization of Japan-Made Vaccines
May 19, 2021
- LDP Study Group’s Draft Proposal Urges Price Maintenance for Patented Drugs
May 19, 2021
- Pharma to Govt: Maintain Prices of Patented Drugs, It’s the Global Standard
May 18, 2021
- MHLW Proposes Lifting Domestic Ban on Cannabis-Derived Drugs, Seeking “Ingredient-Based” Regulation
May 18, 2021
- Japan’s 1st Sakigake-Designated Oncolytic Virus Up for Advisory Panel Review on May 24
May 18, 2021
- AstraZeneca, Moderna COVID-19 Vaccines Up for Key Panel Review on May 20
May 17, 2021
- Japan, Pfizer Agree on 50 Million Extra Vaccine Doses by Sept-End
May 17, 2021
- Eisai’s EZH2 Inhibitor Up for PAFSC Review on May 28
May 17, 2021
- Daiichi Sankyo CEO Urges Rethink of Vaccine Approval System
May 17, 2021
- LDP Project Team Urges Overhaul of Unpredictable Pricing System: Proposal
May 14, 2021
- LDP Panels Call for Emergency Approval Process, Eyes Japan Made Vaccines
May 14, 2021
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…